Cencora reported stronger-than-expected Q3 adjusted earnings and sales, driven by specialty product demand and the OneOncology acquisition. The company also raised its fiscal 2026 EPS guidance, indicating continued positive momentum despite some margin pressure from GLP-1 sales.
Cencora's Q3 results exceeded analyst expectations for both earnings and sales, primarily due to robust demand in specialty products and the strategic acquisition of OneOncology. This positive performance led the company to raise its fiscal 2026 EPS guidance, signaling confidence in its future outlook. While higher GLP-1 sales partially squeezed gross margins, the overall growth in specialty and international segments indicates a strong underlying business. For traders, this suggests a short-term positive sentiment for COR stock, with long-term opportunities tied to its strategic investments in specialty healthcare and digital transformation, though monitoring GLP-1 margin impacts will be crucial.